Connect with us

Hi, what are you looking for?

Jewish Business News


Protalix Biotherapeutics plans $60 million US bond offering


The Gaucher and plant-cell treatment developer is offering a convertible note to US financial institutions.



-/ By Nadav Neuman /

Protalix Biotherapeutics Inc. (NYSE:PLX; TASE: PLX) announced today that it plans offering a $60 million convertible note to institutional investors in the US repayable in 2018. At the same time the company will also offer a further nine million notes, exercisable 30 days after the pricing date of the notes offering.

Protalix has concluded a range of major deals recently, the most important of which was an agreement with the Brazilian Ministry of Health to provide its Gaucher treatment Uplyso and technology transfer to the Brazilian government to build a factory to produce the drug. The company expects revenue of at least $280 million over the next eight years from this deal.

The Gaucher treatment has US Food and Drug Administration (FDA) approval as Elelyso and is marketed through a commercialization agreement with Pfizer Inc. (NYSE: PFE; LSE: PFZ). However, the treatment has been rejected by the European authorities.

Elelyso is the first plant cell-expressed drug derived from ProCellEx, Protalix’s proprietary plant cell-based protein expression system.
Published by 

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.



You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...


The contract signed between the Israeli government and Pfizer shows clearly and unequivocally that this is a clinical study on humans - The agreement...


Now Platika joins and elite club of $10 billion plus Israeli firms.